INTRODUCTION {#s1}
============

Cervical cancer is the second most common female malignancy worldwide. In China, approximately 98,900 new cases were reported in 2015, which accounted for 18.7% of the global incidence \[[@R1]\]. Human papillomavirus (HPV), commonly transmitted through sexual activity, was recognized as an important cause of cervical precancerous lesions or cancer. To date, 14 HPV types have been classified as "high-risk" for their strong carcinogenic potentials. HPV16 and HPV18 are well-known carcinogenic genotypes; additionally, HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 are also strongly associated with cervical cancer \[[@R2], [@R3]\]. In this scenario, numerous epidemiologic studies, most from Europe or the United States, have shown that nearly 100% of patients with cervical cancer test positive for HPV \[[@R3]--[@R6]\]. These results have led to approaches in which HPV testing is an option for primary screening with HPV16/18 genotyping along with a cocktail test of 12 other high-risk HPV (hrHPV) genotypes \[[@R7]\]. HPV testing is more sensitive than cytology in primary screening and offers a longer negative predictive value for cervical cancer \[[@R5]--[@R7]\].

Cervical cancer incidence and mortality have been increasing and are a major public health problem in China. China has the world\'s largest population (approximately 1.37 billion), with approximately 70% of individuals living in rural regions where the incidence of cervical cancer is extremely high \[[@R8]\]. Most cervical cancer screening in China is opportunistic, and cancer incidence rates vary throughout the country \[[@R8], [@R9]\]. In addition, economic factors, education, and HPV genotype distribution, which vary among geographical regions, must also be taken into account. Moreover, comprehensive clinical data on HPV genotype prevalence and relative risk of cervical cancer in Chinese females are lacking.

In this study, we performed a systematic review and meta-analysis of type-specific HPV distribution across the complete spectrum of cervical diagnoses from normal to invasive cervical cancer (ICC). With updated data and detailed analyses, we further evaluated how influential parameters (such as geographical region, HPV DNA source, and PCR primers) affected the results from the meta-analysis.

RESULTS {#s2}
=======

Summary of eligible studies {#s2_1}
---------------------------

We retrieved 1274 citations from the search strategy (Appendix S1), and 190 potentially relevant articles were identified for full-text review. Data were abstracted from 45 eligible studies that met the eligibility criteria \[[@R10]--[@R54]\]. The study flow diagram is shown in Figure [1](#F1){ref-type="fig"}.

![PRISMA flow diagram for identification of studies for meta-analysis](oncotarget-09-15386-g001){#F1}

Study characteristics {#s2_2}
---------------------

Forty-five eligible studies published between 1996 and 2016, including forty-one single-center \[[@R10]--[@R50]\] and four multi-center studies \[[@R51]--[@R54]\], were documented in this review. Among these studies, 12 were conducted in East China \[[@R10]--[@R21]\], 3 in South China \[[@R22]--[@R24]\], 4 in West China \[[@R25]--[@R28]\], 14 in North China \[[@R29]--[@R42]\], 3 in Taiwan \[[@R43]--[@R45]\], 4 in Hong Kong \[[@R46]--[@R49]\], and 1 in Macao \[[@R50]\].

A total of 49,997 eligible women from 32 provinces and municipalities were recruited to participate in these studies (Figure [2](#F2){ref-type="fig"}). Out of 49,997 women tested for overall HPV prevalence, 19,361 (38.7%) had normal cervices, 4877 (9.8%) CIN1, 11,967 (23.9%) CIN2/3, and 13,792 (27.6%) ICCs. The overall HPV distribution stratified by cervical disease grade and geographical region is shown in Table [1](#T1){ref-type="table"}. Eastern China contributed the largest number of samples (20,292, 40.6%), followed by Northern China (13,390, 26.8%), Taiwan (6521, 13.0%), Hong Kong (3297, 6.6%), and Western China (2428, 4.9%). Of the 49,997 women, 1496 (3.0%) were non-Han Chinese women including 1431 Uyghur \[[@R28]\] and 65 Mongolian \[[@R38]\].

![National map of China showing all the geographical sites included in this meta-analysis](oncotarget-09-15386-g002){#F2}

###### Overall HPV prevalence in 49997 women from China, stratified by cervical disease grade and geographical region

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
                       Total\           ICCs\            CIN2/3\          CIN1\            Cervicitis/Normal\                                               
                       (studies = 45)   (studies = 39)   (studies = 32)   (studies = 25)   (studies = 21)                                                   
  -------------------- ---------------- ---------------- ---------------- ---------------- -------------------- -------------- ------ ------------- ------- -------------
  Eastern of China\    20292            10758            5043             4123 (81.8)      3190                 2683 (84.1)    1928   1256 (65.1)   10131   2696 (26.6)
  (studies = 12)                                                                                                                                            

  Southern of China\   1614             1255             1554             1205 (77.5)      60                   50 (83.3)      0      \-            0       \-
  (studies = 3)                                                                                                                                             

  Western of China\    2428             1462             334              293 (87.7)       866                  759 (87.6)     249    168 (67.5)    979     242 (24.7)
  (studies = 4)                                                                                                                                             

  Northern of China\   13390            7329             1940             1803 (92.9)      3826                 3057 (79.9)    1279   796 (62.2)    6345    1673 (26.4)
  (studies =14)                                                                                                                                             

  Taiwan\              6521             4332             2475             2412 (97.5)      1703                 1421 (83.4)    542    322 (59.4)    1801    177 (9.8)
  (studies = 3)                                                                                                                                             

  Hong Kong\           3297             2743             785              747 (95.2)       1622                 1367 (84.3)    785    618 (78.7)    105     11 (10.5)
  (studies = 4)                                                                                                                                             

  Macao\               99               94               36               35 (97.2)        63                   59 (93.7)      0      \-            0       \-
  (studies = 1)                                                                                                                                             

  Multi-center\        2356             2192             1625             1476 (90.8)      637                  630 (98.9)     94     86 (91.5)     0       \-
  (studies = 4)                                                                                                                                             

  Overall\             49997            30165            13792            12094 (87.7)     11967                10026 (83.8)   4877   3246 (66.6)   19361   4799 (24.8)
  (studies = 45)                                                                                                                                            

                                                                                                                                                            
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ICC: invasive cervical cancer; CIN: cervical intraepithelial neoplasia.

Overall HPV prevalence and meta-analysis {#s2_3}
----------------------------------------

A total of 30,165 women were HPV-positive. Overall HPV prevalence increased with the degree of cervical disease severity from 24.8% in normal cervices to 87.7% in ICC (*P* \< 0.001) (Table [1](#T1){ref-type="table"}). The pooled prevalence of overall HPV types among women with ICC was 91.1% (95% CI 88.7--93.1%) and displayed significant heterogeneity, I^2^ = 93.2%, *P* \< 0.0001 (Figure [3](#F3){ref-type="fig"}). Differences in the HPV positivity rate by geographical region varied obviously among pathological categories. In normal cervices, the overall HPV prevalence varied substantially by region, ranging from approximately 10% in Taiwan/Hong Kong to more than 20% in mainland China. For ICC, the overall HPV prevalence was consistent (more than 95%) in Taiwan, Hong Kong, and Macao but ranged from 77.5% to 92.9% and yielded an average of 83.7% (95% CI 82.9--88.2%) in mainland China. The overall HPV prevalence rates in SCC, ADC and unspecified ICC were 86.9% (5840/6721), 71.5% (459/642) and 90.1% (5795/6429), respectively.

![Forest plot of the overall HPV prevalence in cervical cancer](oncotarget-09-15386-g003){#F3}

After stratified by HPV DNA source, we found that the prevalence rates of overall HPV types in cervical cancer from tissues were consistently significantly higher than that from exfoliated cells in all geographical regions (*P* \< 0.05). With regard to PCR primers, HPV prevalence was higher in samples that were tested using SPF1/GP6+ (99.3%, 95% CI 99.0--99.7%) and/or SP10 (95.1%, 95% CI 93.6--96.7%) primers when compared with MY09/11 (86.1%, 95% CI 84.9--87.3%) and/or PGMY09/11 (83.6%, 95% CI 82.6--84.5%) primers (*P* \< 0.001). Meanwhile, the meta-analysis of the HPV prevalence in women with cervical cancer based on HPV DNA source, different region, publication calendar period, and PCR primers is shown in Table [2](#T2){ref-type="table"}.

###### Meta-analysis of the HPV prevalence in women with ICC, stratified by HPV DNA source, across region, publication calendar period, and PCR primers

                                    Total    Cells-based detection   Tissue-based detection                                                                                                                         
  --------------------------------- -------- ----------------------- ------------------------ ----------------------- -------- ---------- -------------- ----------------------- -------- ---------- -------------- -----------------------
  **Total**                         **39**   **12094**               **\<0.0001**             **91.1 (88.7--93.1)**   **24**   **7557**   **\<0.0001**   **89.6 (86.4--92.0)**   **15**   **4537**   **\<0.0001**   **92.9 (87.9--95.9)**
  **Region**                                                                                                                                                                                                        
  Mainland                          28       7424                    \<0.0001                 89.1 (86.3--91.4)       20       6753       \<0.0001       89.1 (85.7--91.7)       8        671        0.0008         89.2 (83.9--92.9)
  Taiwan                            3        2412                    \<0.0001                 94.7 (70.6--99.3)       1        227        NA             NA                      2        2185       \<0.0001       96.8 (57.6--99.9)
  Hong Kong                         4        747                     0.0081                   92.9 (83.9--97.1)       2        425        0.0652         90.1 (68.3--97.5)       2        322        0.0059         98.1 (50.5--99.9)
  Macao                             1        35                      NA                       NA                      0        0          NA             NA                      1        35         NA             NA
  Multi-center                      3        1476                    \<0.0001                 95.9 (81.8--99.2)       1        152        NA             NA                      2        1324       \<0.0001       96.8 (57.6--99.9)
  **Publication calendar period**                                                                                                                                                                                   
  1996-1999                         3        123                     0.7527                   85.9 (79.1--90.7)       1        7          NA             NA                      2        116        0.8364         86.6 (79.7--91.4)
  2000-2009                         13       2857                    \<0.0001                 91.6 (88.2--94.1)       5        918        0.0035         92.0 (87.1--95.2)       8        1939       \<0.0001       91.2 (85.8--94.7)
  2010-2016                         23       9114                    \<0.0001                 91.4 (87.8--94.0)       18       6632       \<0.0001       88.7 (84.9--91.7)       5        2482       \<0.0001       97.3 (81.3--99.7)
  **PCR primers**                                                                                                                                                                                                   
  MY09/11                           15       2741                    \<0.0001                 90.3 (84.2--94.2)       9        2167       \<0.0001       91.2 (79.9--96.4)       6        574        0.0627         89.0 (84.7--92.2)
  PGMY09/11                         14       5221                    \<0.0001                 88.7 (84.6--91.8)       12       4899       \<0.0001       87.8 (83.4--91.1)       2        322        0.0059         98.1 (50.5--99.9)
  SP10                              3        725                     \<0.0001                 93.2 (66.4--98.9)       0        0          NA             NA                      3        725        \<0.0001       93.2 (66.4--98.9)
  SPF1/GP6+                         1        2104                    NA                       NA                      0        0          NA             NA                      1        2104       NA             NA
  MY09/11+GP5+/6+                   6        1303                    0.0003                   90.4 (84.8--94.1)       3        491        0.0092         91.8 (80.6--96.8)       3        812        0.0167         90.3 (80.5--95.5)

95% CI: 95% confidence interval; NA: not available.

Type-specific HPV prevalence and risk of cervical cancer {#s2_4}
--------------------------------------------------------

Type-specific HPV prevalence in HPV-positive women stratified by cervical disease grade is shown in [Supplementary Table 3](#SD4){ref-type="supplementary-material"}. HPV16 was the most frequently detected hrHPV type in every grade. HPV16 positivity rate varied little between cervicitis and normal tissues (22.7%, 95% CI 21.5--24.0%) and CIN1 (23.6%, 95% CI 22.0--25.3%) but increased through CIN2 (37.6%, 95% CI 35.5--39.7%) and CIN3 (51.9%, 95% CI 50.1--53.7%) to reach 65.6% (95% CI 64.7--66.4%) in ICC. HPV18 positivity varied very little between cervicitis and normal tissues and CIN3 (5.6--7.9%) but increased to 12.6% (95% CI 12.0--13.2%) in ICC. HPV58 was the second most common type in ICC (12.6%, 95% CI 12.0--13.2%). Notably, HPV52 was the second most common type in cervicitis/CIN1/CIN2 (16.3--22.0%), but the prevalence rate decreased remarkably through CIN3 (15.7%, ranked third) and reduce to 6.5% in ICC (ranked fourth). For the next five most common hrHPV types in ICC, including HPV33, 31, 59, 45, and 39, the positivity rate ranged from 2.1% to 5.5%. For the next five least common hrHPV types in ICC, including HPV51, 56, 68, 35, and 66, the positivity rate ranged from 0.7% to 1.4%. HPV16, 18 and 45 were the only hrHPV types found more frequently in ICC than in cervicitis/normal samples, with the ICC:cervicitis/normal ratios of 2.9, 2.2 and 1.4, respectively. HPV31, 33, 52, and 58 were more frequent in CIN3 in comparison with cervicitis/normal samples, but less common in ICC compared with CIN3 (ICC:CIN3 ratios ranging from 0.6 for HPV58 and down to 0.4 for HPV52). HPV16, 18, 35, 39, 45, and 59 were more frequent in ICC than CIN3, with ICC:CIN3 ratios ranging from 2.3 for HPV18 to 1.1 for HPV35/45.

When stratified by geographical region, we found increased HPV16 positivity with lesion severity to be similar in all regions, with ICC:cervicitis/normal ratios ranging from 2.4 in North China to 4.2 in East China (Figure [4](#F4){ref-type="fig"} and [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). The increased HPV18 positivity between normal and ICC cases was observed across all regions, with ICC:cervicitis/normal ratios between 1.8 and 4.1. For HPV58 and HPV52, a relatively elevated in ICC:cervicitis/normal ratio (2.9 and 3.9, respectively) was observed in West China and not apparent in other regions. With regard to HPV DNA source, we found that the prevalence of type-specific HPV in HPV-positive women with cervical cancer based on exfoliated cells were universally higher than that in tissues. HPV58 was the second most common type in exfoliated cells but ranked third in tissues (Table [3](#T3){ref-type="table"}).

![Type-specific HPV distribution by geographic region in Chinese women with ICC](oncotarget-09-15386-g004){#F4}

Study quality and publication bias {#s2_5}
----------------------------------

The quality assessment of all eligible studies was based on the Agency for Healthcare Research and Quality (AHRQ) scale, which is shown in [Supplementary Table 2](#SD3){ref-type="supplementary-material"}, and the assessment results provided reasonable confidence in the reliability of the meta-analysis. The methodological quality assessment was considered high in thirty-four studies \[[@R10]--[@R15], [@R17], [@R19]--[@R23], [@R25]--[@R32], [@R39]--[@R45], [@R47]--[@R53]\] and moderate in eleven studies \[[@R16], [@R18], [@R24], [@R33]--[@R38], [@R46], [@R54]\]. Five studies had full scores for the representativeness of the cross-sectional study \[[@R10], [@R17], [@R20], [@R23], [@R43]\], but most of them lacked scores because subjects were not consecutive. Other studies lacked scores for incomplete follow-up data. Egger\'s and Begg\'s tests were performed to assess the publication bias and proved to be insignificant (both *P* = 0.33).

DISCUSSION {#s3}
==========

HPV is a sexually transmitted infection, and high-risk HPV types have been shown to be the etiological agents of cervical cancer. Two meta-analyses have been published on the distribution of HPV types in the cervix among Chinese females, but the results were controversial \[[@R55], [@R56]\]. First, selected samples were identified by cytology or histology for study inclusion criteria. It is worth noting that the distribution of HPV types in cytology findings is different from those in histology assessment, which is the gold standard for diagnosis. Second, HPV testing might be especially useful for the detection of ADC, which can be difficult to identify using cytology \[[@R57]\]. Our study is the first to analyze nationwide clinical data on HPV types across the complete spectrum of cervical disease confirmed by cervical pathological diagnosis. The objective was to compare the correlation between type-specific HPV infections and the risk of cervical cancer. With the updated data and more detailed analysis, in this study, geographical region, HPV DNA source, and PCR primers, which have not been included in previous studies, were further analyzed.

In these summarized data from China, we found that HPV16 was the most frequently detected hrHPV type in each cervical disease grade, and the positivity rate steadily increased from normal histology to ICCs among all geographical regions ([Supplementary Table 1](#SD2){ref-type="supplementary-material"} and [Supplementary Table 3](#SD4){ref-type="supplementary-material"}), indicating an increased long-term risk for cervical cancer with HPV16 infection \[[@R58]--[@R60]\]. The same pattern was found for HPV18. The pooled prevalence rates of HPV16 and 18 in cervical cancer were 66.8% (95% CI 62.5--70.8%) ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}) and 11.8% (95% CI 9.8--14.1%) ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}), respectively. Our data showed that the HPV16 positivity rate was similar to the previously published global data (64.7 ± 3.6%) but lower for HPV18 (16.5 ± 2.9%) \[[@R58]\]. Compared with the rest of the world, the HPV16/18 prevalence for ICCs (78.2%) in this study was similar to that reported for Eastern Asia (77.5%), lower than Western/Central Asia (88.1%), Europe (83.1%), and North America (80.8%), and higher than Latin America (66.4%) \[[@R58], [@R61]\]. These results strengthen the hypothesis that the distribution of HPV16/18 variants is related to geographical or racial distribution \[[@R62]\], and HPV variants that differ in their biological properties may present differences in carcinogenic potential.

Consistent with previous epidemiological studies, HPV16, 52 and 58 were the dominant hrHPV types in the general Chinese population \[[@R63], [@R64]\]. Our analysis showed that HPV52 and 58 were the 2nd and 3rd most common hrHPV types among women with lower grade lesions. The HPV52 positivity rate decreased remarkably from normal histology (16.3%, ranked second) to ICC (6.5%, ranked fourth), but HPV58 was still the common type in ICC (12.6%, ranked second). These findings showed that HPV52 and 58 were important etiological agents for cervical carcinogenesis in China; however, HPV52 was less carcinogenic than HPV58. In addition, HPV52 and 58 were more frequent in CIN3 than in normal cervices, but less common in ICCs. This pattern was also observed for HPV31 and HPV33. These results suggested that HPV31, 33, 52, and 58 could confer higher risks for CIN3 than other non-HPV16/18 types, supporting the results from previous studies \[[@R58]--[@R60], [@R65]\].

Alpha-7 species containing HPV18, 39, 45, 59 and 68, which are proportionally overrepresented in ADC \[[@R66]\], are known to be less efficiently detected by routine cytological screening \[[@R67], [@R68]\]. In the present meta-analysis, a total of 5480 SCC and 459 ADC cases with positive HPV status were included ([Supplementary Table 4](#SD5){ref-type="supplementary-material"}). ADC constituted less than 8% of all ICCs; therefore, the type-specific HPV prevalence in ICC is mainly driven by the findings for SCC. Our results confirmed that alpha-7 HPV types are significantly higher in ADC (46.9%) than in SCC (10.1%) (*P* \< 0.001). Moreover, HPV18 was the most common alpha-7 type (44.4% in ADC vs. 9.1% in SCC), and similar patterns were also found for HPV39, 45, 59 and 68.

HPV35, 51, 56, 66, and 68 types found in \< 1.5% of ICC represented an important proportion of low-grade cervical lesions. The lower ICC:normal ratios suggested that such types have relatively low carcinogenic potential. Of note, the ICC:normal ratios for HPV45 and HPV58 were consistently higher, suggesting a higher carcinogenic potential compared with all other non-HPV16/18 types.

Meta-analysis on the prevalence of overall HPV types showed a higher rate detected in a subgroup of tissues than in exfoliated cells (Table [2](#T2){ref-type="table"}). However, the prevalence of type-specific HPV in HPV-positive women with cervical cancer based on cells was universally higher than that on tissues (Table [3](#T3){ref-type="table"}). Our findings suggested that the HPV prevalence in cells did not correspond well to that observed in tissues. It should be noted that the complex link between historical infections and current disease status might be related to HPV genome integration status \[[@R69]\]. In addition, HPV type-specific primers are usually designed to amplify shorter sequences of HPV DNA and might be more sensitive for detection of HPV DNA sequences. Indeed, our study showed that the HPV detection rate of ICC in Taiwan was much higher using SPF1/GP6+ (99.3%, 95% CI 99.0--99.7%) to amplify an 184-bp fragment when compared with other PCR primer sets.

It is necessary to consider the limitations of our meta-analysis while interpreting the results. First, potential heterogeneity associated with the cross-sectional study design and its inherent risk of bias, including the variations in population characteristics, PCR-based HPV detection protocols, quality of diagnosis and cervical screening strategies among the studies, must be considered. Second, heterogeneity could not be ruled out even given the pre-designed subgroup analysis by geographical region, PCR primer sets and publication calendar period. To address this issue, we chose the random effect model meta-analysis to combine data. Third, 77.4% of the patients included in the meta-analysis came from only two macro-geographical regions of mainland China (40.6% in the East and 26.8% in the North, respectively). Thus, one should be cautious when extrapolating our summary results to all regions of China. Fourth, several studies did not include for a broad range for type-specific HPV \[[@R15], [@R38]--[@R40], [@R46], [@R51], [@R53]\].

Our present meta-analysis suggested a significantly increased risk of cervical cancer associated with high-risk HPV genotype infection. HPV16, 18 and 58 were the most frequently observed genotypes in cervical cancer specimens and showed a strong association with the development of cancer. However, the association between type-specific HPV distribution and cervical cancer risk was slightly influenced by factors such as geographical regions, HPV DNA sources, and PCR primers. It should be noted that the laboratory standardization and quality assurance of HPV genotyping methods may increase data comparability and improve virological surveillance in the future vaccine era of China.

MATERIALS AND METHODS {#s4}
=====================

Consent statement {#s4_1}
-----------------

As this study was a systematic review and meta-analysis, we did not include any humans and/or animals. This study was approved by the Institutional Medical Ethics Review Board of Taizhou Hospital in Zhejiang Province.

Search strategy {#s4_2}
---------------

This meta-analysis was performed in adherence with the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) \[[@R70]\] ([Supplementary Table 5](#SD6){ref-type="supplementary-material"}, PRISMA Checklist). We used PubMed/MEDLINE (NCBI), the Cochrane Central Register of Controlled Trials (Wiley), China National Knowledge Infrastructure (CNKI), and the VIP database for Chinese Technical Periodicals (VIP) to search for relevant articles published from the earliest date available to November 15, 2016. The search strategy is described in Appendix S1. Furthermore, we reviewed the references cited in the retrieved articles to search for additional relevant studies.

Eligibility criteria {#s4_3}
--------------------

The participants were females from China who were included in studies of cervical disease associated with HPV. Eligible studies met the following inclusion criteria: 1) using consensus PCR primers, 2) overall and type-specific HPV elicitation, and 3) confirmed by cervical pathological diagnosis. The exclusion criteria were as follows: 1) duplicated data, 2) reviews, letters, conference reports or degree thesis, 3) studies on HIV patients or other sexually transmitted pathogens, 4) studies on gestational or vaccinated women, 5) HPV genotypes not stratified by lesion grade or fewer than 10 cases, and 6) HPV DNA types fewer than 3 high-risk genotypes identified.

Data extraction {#s4_4}
---------------

Two investigators (SS. Dong and XJ. Feng) independently extracted data from eligible studies. Disagreements were resolved by discussion or involvement of a third investigator (HH. Xu). For each eligible study, the following items were extracted: first author, publication year, region of China, study design, HPV DNA source, PCR primers, pathological diagnosis, sample size, and the number of overall or type-specific HPV-positive samples. For a subset of studies reporting such data, the overall prevalence of multiple infections (which may also include low-risk HPV types) was also extracted. Detail information on all included studies is presented in [Supplementary Table 4](#SD5){ref-type="supplementary-material"}. Each study was classified according to the following criteria: 1) four macro-geographical regions of mainland China (East, West, South, and North, respectively), Taiwan, Hong Kong, and Macao, 2) HPV DNA source (exfoliated cells, fresh biopsies, fixed biopsies), and 3) histological diagnosis (CIN1, CIN2, CIN3, ICC, squamous cell carcinoma (SCC), or adeno/adenosquamous carcinoma (ADC)).

Quality assessment {#s4_5}
------------------

Two investigators (LZ. Zheng and A. Lin) independently assessed the quality/risk of bias for each eligible study according the quality assessment forms from the AHRQ (<https://www.ncbi.nlm.nih.gov/books/NBK35156/>) \[[@R71]\]. A third investigator (K. Wang) resolved the disagreements. In this meta-analysis, the methodological quality of all eligible studies was assessed by AHRQ and included an 11-item yes/no/unclear response option: the "Yes" was scored as "1", and "No" or "Unclear" was scored "0". Study quality was assessed as follows: high quality = 8--11; moderate quality = 4--7; low quality = 0--3.

Statistical analysis {#s4_6}
--------------------

We calculated the prevalence of the overall HPV and type-specific HPV (14 high-risk HPV types: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68; 2 low-risk HPV types: HPV 6 and 11) among Chinese women with cervical precancerous lesions and ICCs. Type-specific HPV prevalence was defined as the proportion of HPV-positive women in which a particular HPV type was detected, so sample sizes differed among the type-specific analyses. Odds ratios (ORs) and relative 95% confidence intervals (95% CI) were calculated using SPSS version 15.0 (SPSS Inc., Chicago, IL). *P* values were two-sided, and statistical significance was accepted if the *P* value was 0.05 or less.

Meta-analysis was conducted using a random effects model. The I^2^ statistic quantified the heterogeneity among the studies, and *P* \< 0.10 was considered indicative of significant heterogeneity. Forest plots were used to display the results graphically. To examine the potential publication bias, we used the Egger\'s and Begg\'s tests, where *P* \< 0.05 was considered to be statistically significant. All analyses were performed using the R statistical software, and the Metaprop command was used as it provides appropriate methods for dealing with proportions with 100% \[[@R72]\].

###### Type-specific HPV prevalence in HPV-positive women with cervical cancer, stratified by HPV DNA source

                          Total   Cells-based detection   Tissue-based detection                                                   
  ----------------------- ------- ----------------------- ------------------------ ------ ------ ------------------- ------ ------ -------------------
  **Type-specific HPV**                                                                                                            
  HPV16                   12020   7882                    65.6 (64.7--66.4)        7483   5021   67.1 (66.0--68.2)   4537   2861   63.1 (61.7--64.5)
  HPV18                   12020   1516                    12.6 (12.0--13.2)        7483   841    11.2 (10.5--12.0)   4537   675    14.9 (13.8--15.9)
  HPV58                   11984   1507                    12.6 (12.0--13.2)        7476   1005   13.4 (12.7--14.2)   4508   502    11.1 (10.2--12.1)
  HPV52                   11744   759                     6.5 (6.0--6.9)           7324   488    6.7 (6.1--7.2)      4420   271    6.1 (5.4--6.8)
  HPV33                   11099   608                     5.5 (5.1--5.9)           7483   376    5.0 (4.5--5.5)      3616   232    6.4 (5.6--7.2)
  HPV31                   11181   393                     3.5 (3.2--3.9)           7476   291    3.9 (3.5--4.3)      3705   102    2.8 (2.2--3.3)
  HPV59                   7178    186                     2.6 (2.2--3.0)           3640   115    3.2 (2.6--3.7)      3538   71     2.0 (1.5--2.5)
  HPV45                   5659    118                     2.1 (1.7--2.5)           2902   35     1.2 (0.8--1.6)      2757   83     3.0 (2.4--3.6)
  HPV39                   7337    162                     2.2 (1.9--2.5)           4066   83     2.0 (1.6--2.5)      3271   79     2.4 (1.9--2.9)
  HPV51                   4931    69                      1.4 (1.1--1.7)           2336   41     1.8 (1.2--2.3)      2595   28     1.1 (0.7--1.5)
  HPV56                   5648    74                      1.3 (1.0--1.6)           3141   51     1.6 (1.2--2.1)      2507   23     0.9 (0.5--1.3)
  HPV68                   3582    48                      1.3 (1.0--1.7)           3035   42     1.4 (1.0--1.8)      547    6      1.1 (0.2--2.0)
  HPV35                   5131    60                      1.2 (0.9--1.5)           2456   32     1.3 (0.9--1.8)      2675   28     1.0 (0.7--1.4)
  HPV66                   2338    16                      0.7 (0.4--1.0)           1874   16     0.9 (0.4--1.3)      464    0      NA

95% CI: 95% confidence interval; NA: not available.
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